Industry
Biotechnology
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Avi Kapoor
July 15, 2024 | 5:23 pm
Portfolio Pulse from Benzinga Newsdesk
June 27, 2024 | 12:17 pm
Portfolio Pulse from Benzinga Newsdesk
May 23, 2024 | 6:46 pm
Portfolio Pulse from Benzinga Newsdesk
May 23, 2024 | 11:14 am
Portfolio Pulse from Benzinga Insights
May 21, 2024 | 12:06 pm
Portfolio Pulse from Benzinga Newsdesk
May 01, 2024 | 4:08 pm
Portfolio Pulse from Benzinga Newsdesk
April 19, 2024 | 8:42 pm
Portfolio Pulse from Benzinga Newsdesk
March 21, 2024 | 12:54 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.